.svg)
You are now leaving Astellas.us. The website you are linking to is neither owned nor controlled by Astellas.
Astellas is not responsible for the content or services on this site.
News Releases
Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
May 29, 2020XTANDI is now MHLW-approved for both metastatic hormone-sensitive prostate cancer and castration-resistant prostate cancer in Japan
-
May 20, 2020Submission for the treatment of anemia in adult patients with chronic kidney disease
-
Feb 19, 2020- Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -
-
Feb 10, 2020- After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination - - Findings To Be Presented During an Oral Session at the 2020 Genitourinary Cancers Symposium -
Feb 10, 2020- New Funding will Address Disparities in Mental Health Diagnosis and Treatment for 400,000 People in Need -